Abstract
The orexin system is a potential treatment target for drug addiction. Orexin-1 receptor (OxR1) antagonism reduces demand for cocaine and remifentanil, indicating that orexin-based therapies may reduce demand for many classes of abused drugs. However, pharmacokinetics vary greatly among opioids and it is unclear if OxR1 antagonism would reduce demand for all opioids, particularly ones with high abuse liability. Here, we established a behavioral economics (BE) procedure to assess the effects of OxR1 antagonism on demand for the highly abused opioid fentanyl. We also investigated the utility of our procedure to predict OxR1 antagonism efficacy and relapse propensity. Demand parameters α (demand elasticity or price sensitivity of consumption, an inverse measure of drug motivation) and Qo (drug consumption at null cost) were assessed. The OxR1 antagonist SB-334867 (SB) decreased motivation (increased α) for fentanyl without affecting Qo. Baseline α values predicted SB efficacy, such that SB was most effective at reducing motivation (increasing α) in highly motivated rats. Baseline α values predicted the amount of cued reinstatement of fentanyl seeking; this reinstatement behavior was attenuated by SB administration. These results highlight the promise of the orexin system as a treatment target for opioid addiction and emphasize the usefulness of BE procedures in the study of opioid abuse.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52.
Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59:385–90.
MacKillop J, Goldenson NI, Kirkpatrick MG, Leventhal AM. Validation of a behavioral economic purchase task for assessing drug abuse liability. Addict Biol. 2018;24:303–14.
Bruner NR, Johnson MW. Demand curves for hypothetical cocaine in cocaine-dependent individuals. Psychopharmacology. 2014;231:889–97.
Pickover AM, Messina BG, Correia CJ, Garza KB, Murphy JG. A behavioral economic analysis of the nonmedical use of prescription drugs among young adults. Exp Clin Psychopharmacol. 2016;24:38–47.
MacKillop J, Murphy JG, Ray LA, Eisenberg DT, Lisman SA, Lum JK, et al. Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers. Exp Clin Psychopharmacol. 2008;16:57–65.
Bickel WK, DeGrandpre RJ, Higgins ST. Behavioral economics: a novel experimental approach to the study of drug dependence. Drug Alcohol Depend. 1993;33:173–92.
Murphy JG, MacKillop J, Skidmore JR, Pederson AA. Reliability and validity of a demand curve measure of alcohol reinforcement. Exp Clin Psychopharmacol. 2009;17:396–404.
Bentzley BS, Jhou TC, Aston-Jones G. Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat. Proc Natl Acad Sci USA. 2014;111:11822–7.
Porter-Stransky KA, Bentzley BS, Aston-Jones G. Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil. Addict Biol. 2017;22:303–17.
Hursh SR, Silberberg A. Economic demand and essential value. Psychol Rev. 2008;115:186–98.
Fragale JE, Beck KD, Pang KC. Use of the exponential and exponentiated demand equations to assess the behavioral economics of negative reinforcement. Front Neurosci. 2017;11:77.
Christensen CJ, Silberberg A, Hursh SR, Roma PG, Riley AL. Demand for cocaine and food over time. Pharmacol Biochem Behav. 2008;91:209–16.
Hursh SR. Behavioral economics of drug self-administration and drug abuse policy. J Exp Anal Behav. 1991;56:377–93.
Bickel WK, Yi R, Mueller ET, Jones BA, Christensen DR. The behavioral economics of drug dependence: towards the consilience of economics and behavioral neuroscience. Curr Top Behav Neurosci. 2010;3:319–41.
Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, et al. Orexin/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol. 2015;172:334–48.
Sharf R, Sarhan M, Dileone RJ. Role of orexin/hypocretin in dependence and addiction. Brain Res. 2010;1314:130–8.
Kenny PJ. Tobacco dependence, the insular cortex and the hypocretin connection. Pharmacol Biochem Behav. 2011;97:700–7.
Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol. 2006;148:752–9.
Prasad AA, McNally GP. Effects of vivo morpholino knockdown of lateral hypothalamus orexin/hypocretin on renewal of alcohol seeking. PLoS One. 2014;9:e110385.
Rasmussen K, White DA, Acri JB. NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology. 2018;44:657–9.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573–85.
Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci. 2006;26:398–405.
Sharf R, Guarnieri DJ, Taylor JR, DiLeone RJ. Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Res. 2010;1317:24–32.
Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005;437:556–9.
Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci. 2012;35:798–804.
Borgland SL, Chang SJ, Bowers MS, Thompson JL, Vittoz N, Floresco SB, et al. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci. 2009;29:11215–25.
Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18:S3–13.
Hug CC Jr., Murphy MR. Tissue redistribution of fentanyl and termination of its effects in rats. Anesthesiology. 1981;55:369–75.
Wade CL, Vendruscolo LF, Schlosburg JE, Hernandez DO, Koob GF. Compulsive-like responding for opioid analgesics in rats with extended access. Neuropsychopharmacology. 2015;40:421–8.
Bentzley BS, Aston-Jones G. Orexin-1 receptor signaling increases motivation for cocaine-associated cues. Eur J Neurosci. 2015;41:1149–56.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63.
Brodnik ZD, Alonso IP, Xu W, Zhang Y, Kortagere S, Espana RA. Hypocretin receptor 1 involvement in cocaine-associated behavior: therapeutic potential and novel mechanistic insights. Brain Res. 2018. (in press)
James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats. Eur J Neurosci. 2018. https://doi.org/10.1111/ejn.14166.
Reiner DJ, Fredriksson I, Lofaro OM, Bossert JM, Shaham Y. Relapse to opioid seeking in rat models: behavior, pharmacology and circuits. Neuropsychopharmacology. 2018;44:465–77.
Cason AM, Aston-Jones G. Role of orexin/hypocretin in conditioned sucrose-seeking in rats. Psychopharmacology. 2013;226:155–65.
Edwards S, Vendruscolo LF, Schlosburg JE, Misra KK, Wee S, Park PE, et al. Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF(1) receptor antagonism. Neuropharmacology. 2012;62:1142–51.
Park PE, Schlosburg JE, Vendruscolo LF, Schulteis G, Edwards S, Koob GF. Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. Addict Biol. 2015;20:275–84.
Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci. 2003;23:3106–11.
Hollander JA, Pham D, Fowler CD, Kenny PJ. Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front Behav Neurosci. 2012;6:47.
Smith RJ, See RE, Aston-Jones G. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci. 2009;30:493–503.
Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR. The hypocretin–orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31:336–48.
Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA. 2005;102:19168–73.
James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased number and activity of a lateral subpopulation of hypothalamic orexin/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry. 2018;85:925–35.
Moorman DE, Aston-Jones G. Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol-preferring Sprague–Dawley rats. Alcohol. 2009;43:379–86.
Moorman DE, James MH, Kilroy EA, Aston-Jones G. Orexin/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats. Brain Res. 2017;1654:34–42.
James MH, Mahler SV, Moorman DE, Aston-Jones G. A decade of orexin/hypocretin and addiction: where are we now? Curr Top Behav Neurosci. 2017;33:247–81.
Plaza-Zabala A, Flores A, Maldonado R, Berrendero F. Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. Biol Psychiatry. 2012;71:214–23.
Moorman DE, James MH, Kilroy EA, Aston-Jones G. Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner. Eur J Neurosci. 2016;43:710–20.
Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE, Grigoriadis D, et al. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology. 2015;40:1123–9.
Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006;29:571–7.
Acknowledgements
The authors would like to thank Veronica Behman for her assistance in performing behavioral experiments for this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fragale, J.E., Pantazis, C.B., James, M.H. et al. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacol. 44, 1690–1697 (2019). https://doi.org/10.1038/s41386-019-0420-x
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41386-019-0420-x
This article is cited by
-
Genetic associations between orexin genes and phenotypes related to behavioral regulation in humans, including substance use
Molecular Psychiatry (2025)
-
Orexin receptors: possible therapeutic targets for psychiatric disorders
Psychopharmacology (2025)
-
Hypocretin-1 receptor antagonism improves inhibitory control during the Go/No-Go task in highly motivated, impulsive male mice
Psychopharmacology (2024)
-
Intermittent nicotine access is as effective as continuous access in promoting nicotine seeking and taking in rats
Psychopharmacology (2024)
-
Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models
Nature Communications (2024)
